MTOR and cancer: The mTOR inhibitor effects as cancer monotherapy have been limited, perhaps because they only exhibit poor proapoptotic activity, being mainly cytostatic and because of the existence of a negative feedback loop on PI3K/Akt, resulting in enhanced PI3K/Akt upon mTOR inhibition.